HIV Vaccine Trial Participation Among Ethnic Minority Communities
- 1 February 2006
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 41 (2) , 210-217
- https://doi.org/10.1097/01.qai.0000179454.93443.60
Abstract
Background: Underrepresentation of ethnic minority communities limits the generalizability of HIV vaccine trial results. We explored perceived barriers and motivators regarding HIV vaccine trial participation among low-socioeconomic ethnic minority respondents at risk for HIV. Methods: Six focus group interviews were conducted using a semistructured interview guide. Participants (N = 58, mean age = 36 years, 37% female, and 56% Latino/a and 35% African American) were recruited using venue-based sampling in Los Angeles. Data were analyzed using narrative thematic analysis and Ethnograph qualitative software. Results: Perceived barriers to HIV vaccine trial participation, in rank order, were (1) vaccine-induced HIV infection, (2) physical side effects, (3) uncertainty about vaccine efficacy, (4) uncertainty about other vaccine characteristics, (5) mistrust, (6) low perceived HIV risk, (7) study demands, (8) stigma, and (9) vaccine-induced HIV seropositivity. Motivators were (1) protection against HIV infection, (2) free insurance and/or medical care, (3) altruism, and (4) monetary incentives. Conclusions: Population-specific HIV vaccine trial recruitment and implementation strategies should address trial risks from a family perspective, cultural gender norms, mistrust, low perceived HIV risk, the importance of African-American and Latino/a community participation in HIV vaccine trials, and misconceptions about gaining protection against HIV infection. Increasing the cultural relevance of trial recruitment and implementation should facilitate the participation of Latinos/as and African Americans in HIV vaccine trials.Keywords
This publication has 40 references indexed in Scilit:
- Demographic Factors That Influence the Neutralizing Antibody Response in Recipients of Recombinant HIV‐1 gp120 VaccinesThe Journal of Infectious Diseases, 2004
- HIV risk and prevention in a post-vaccine contextVaccine, 2004
- A Sound Rationale Needed for Phase III HIV-1 Vaccine TrialsScience, 2004
- Readiness for HIV Vaccine Trials: Changes in Willingness and Knowledge Among High-Risk Populations in the HIV Network for Prevention TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Do Blacks Believe That HIV/AIDS Is a Government Conspiracy against Them?Preventive Medicine, 1999
- Willingness to Participate in HIV-1 Vaccine Efficacy Trials and the Effect of Media Events Among Gay and Bisexual Men in New York CityJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Feasibility of Human Immunodeficiency Virus Vaccine Trials in Homosexual Men in the United States: Risk Behavior, Seroincidence, and Willingness to ParticipateThe Journal of Infectious Diseases, 1996
- Acculturation and Its Effects on Self-Esteem among Immigrant Latina WomenBehavioral Medicine, 1996
- Interest among Gay/Bisexual Men in Greater Boston in Participating in Clinical Trials of Preventive HIV VaccinesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Gender, culture, and power: Barriers to HIV‐prevention strategies for womenThe Journal of Sex Research, 1996